- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: CP-868596, ARO 002 中文名稱:克萊拉尼
Crenolanib是一種有效的,選擇性PDGFRα/β抑制劑,在CHO細胞中Kd為2.1 nM/3.2 nM,也能有效抑制FLT3,對D842V突變型敏感對V561D突變型不敏感,作用于PDGFR比作用于c-Kit,VEGFR-2,TIE-2,F(xiàn)GFR-2,EGFR,erbB2,和Src的選擇性高100倍以上。Crenolanib可輔助誘導(dǎo)線粒體自噬。
Crenolanib Chemical Structure
CAS: 670220-88-9
相關(guān)靶點 | PDGFRα PDGFRβ | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | CP-673451 Orantinib (SU6668) Tyrphostin AG 1296 Trapidil PP121 AZD2932 | 點擊展開 |
相關(guān)化合物庫 | 激酶抑制劑庫 酪氨酸激酶抑制劑分子庫 PI3K/Akt 抑制劑庫 細胞周期化合物庫 血管生成相關(guān)化合物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
A549 cells | Cell viability assay | 3.9-1000 nM | 72 h | a dose-dependent inhibition of cancer cell viability | 25328409 |
MV4-11 | Cytotoxicity assay | 0.5 to 5000 nM | 2 to 8 hrs | Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability at 0.5 to 5000 nM incubated for 2 to 8 hrs followed by compound washout by CellTiter-Glo luminescent assay | 30742435 |
MV4-11 | Cytotoxicity assay | 72 hrs | Cytotoxicity in human MV4-11 cells assessed as inhibition of cellular viability incubated for 72 hrs by CellTiter-Blue assay, IC50=0.012μM | 30742435 | |
MV4-11 | Function assay | a decrease in mitochondrial matrix protein aconitase hydratase 2 (ACO2) | 25328409 | ||
MV4-11 | Cytotoxicity assay | Cytotoxicity against human MV4-11 cells expressing FLT3 ITD mutant, IC50=0.0015μM | 31207462 | ||
MOLM13 | Cytotoxicity assay | Cytotoxicity against human MOLM13 cells expressing FLT3 ITD mutant, IC50=0.0049μM | 31207462 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 29435139 | ||
U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Crenolanib是一種有效的,選擇性PDGFRα/β抑制劑,在CHO細胞中Kd為2.1 nM/3.2 nM,也能有效抑制FLT3,對D842V突變型敏感對V561D突變型不敏感,作用于PDGFR比作用于c-Kit,VEGFR-2,TIE-2,F(xiàn)GFR-2,EGFR,erbB2,和Src的選擇性高100倍以上。Crenolanib可輔助誘導(dǎo)線粒體自噬。 | ||||||
---|---|---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Crenolanib顯著有效,能夠抑制耐藥的PDGFRα激酶(D842I,D842V,D842Y,D1842-843IM,和缺失I843)活性。Crenolanib作用于同基因模型系統(tǒng)中D842V,IC50大約為10 nM。Crenolanib抑制EOL-1細胞中融合致癌基因的激酶活性,其衍生自慢性噬酸細胞白血病患者,且表達持續(xù)活化的FIP1L1- PDGFRα融合激酶,IC50 = 21 nM。Crenolanib也會抑制EOL-1細胞的增殖,IC50 = 0.2 pM。Crenolanib抑制在BaF3細胞中表達的V561D或D842V突變激酶的活化,IC50分別為85 nM或272 nM。Crenolanib抑制H1703非小細胞肺癌細胞系中PDGFRα活化,其能夠使包含PDGFRα基因座的4q12區(qū)域擴增24倍,IC50為26 nM。[1] Crenolanib是一種口服具有生物活性的,高度有效的,選擇性PDGFR TKI。Crenolanib是苯并咪唑化合物,對PDGFRA和PDGFRB的IC50s分別為0.9 nM和1.8 nM。[2] |
|||
---|---|---|---|---|
激酶實驗 | PDGFRα激酶活性的生物化學(xué)評估 | |||
中國倉鼠卵巢(CHO)細胞用突變型或野生型PDGFRα瞬時轉(zhuǎn)染,用不同濃度的Crenolanib處理。涉及重組DNA的實驗使用2級生物安全條件,根據(jù)指南進行。制備來自細胞系的蛋白質(zhì)裂解物,使用抗PDGFRα抗體進行免疫沉淀反應(yīng),然后用于PDGFRα的連續(xù)免疫印跡。使用Photoshop軟件進行密度測定以量化藥物作用,磷酸-PDGFRα的水平標(biāo)歸一化到總蛋白質(zhì)。密度測定法和增殖實驗結(jié)果使用Calcusyn 2.1軟件分析,以精確測定IC50值。使用Wilcoxon Rank Sum Test比較Crenolanib對給定突變體的IC50值。 | ||||
細胞實驗 | 細胞系 | EOL-1 細胞系 | ||
濃度 | 0-20 pM | |||
孵育時間 | 72小時 | |||
方法 | 將細胞以20, 000細胞/孔的密度加入96孔板,與Crenolanib培育72小時,然后使用2,3-bis[2-甲氧基-4-硝基-5-磺苯基]-2H-四唑-5-羰基苯胺 (XTT)-試驗測量細胞增殖。 |
|||
實驗圖片 | 檢測方法 | 檢測指標(biāo) | 實驗圖片 | PMID |
Western blot | pKIT / KIT pFLT3 / FLT3 / pERK / ERK / pS6 / S6 pAKT / AKT / pMAPK / MAPK / pSTAT5 / STAT5 | 24623852 | ||
Growth inhibition assay | Cell viability | 24623852 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT00949624 | Completed | Advanced Solid Tumors |
Arog Pharmaceuticals Inc. |
December 2005 | Phase 1 |
分子量 | 443.54 | 分子式 | C26H29N5O2 |
CAS號 | 670220-88-9 | SDF | Download Crenolanib SDF |
Smiles | CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4 | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 88 mg/mL ( (198.4 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Ethanol : 88 mg/mL (198.4 mM) Water : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項